Glenmark Pharmaceuticals has announced that it plans to commence shipping of oral contraceptive drug, drospirenone and ethinyl estradiol tablet, immediately following the grant of final approval for the product from the United States Food & Drug Administration (US FDA). The oral contraceptive is a generic version of Bayer Healthcare Pharmaceuticals' Yaz tablet.
"Glenmark Pharmaceuticals Inc, USA has been granted final approval by US FDA for drospirenone and ethinyl estradiol tablets USP, 3 mg/0.02 mg," the company said in a BSE filing on August 19, 2015.
According to IMS Health sales data, Yaz market achieved annual sales of approximately $170.1 million for the 12 months period ending June 2015.
"Glenmark Pharmaceuticals Inc, USA has been granted final approval by US FDA for drospirenone and ethinyl estradiol tablets USP, 3 mg/0.02 mg," the company said in a BSE filing on August 19, 2015.
According to IMS Health sales data, Yaz market achieved annual sales of approximately $170.1 million for the 12 months period ending June 2015.